Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Torben Noerup Nielsen who wrote (15658)	2/23/1998 2:29:00 AM
From: CYBERKEN	Read Replies (1) \| Respond to of 32384

Regarding viruses, I expect that biotech will eventually solve the problems of viruses. The company that gets there first will have access to a huge market. Regarding Ligand stopping late stage trials due to overwhelming effectiveness of the drug, it's happened once already (panretin for KS). If it happens with a large-market indication, Ligand will immediately become that "household word" we keep hoping for. Regarding Ligand management, most of us who are long have been so in part because it's difficult if not impossible to find better mgt in the sector. With panretin, that's no longer a speculation. Their record is and will continue to speak for itself. Regarding Ligand at 100 by June, 00, Tony will be trying to holler it down TO 100 by then. ("Dammit! That last 10K at 125 was a SELL!")(:->)

To: Torben Noerup Nielsen who wrote (15658)	2/23/1998 7:29:00 AM
From: Bryce Elkins	Read Replies (1) \| Respond to of 32384

Torben - re: Cancer is a lot worse in my mind. I concur completely; since my wife developed this disease and died from it, I've found that everybody I talk to about cancer has either a direct experience with it or some immediate family has had a bout with it. I know of no other disease with this ubiquity since the plagues of Europe.

To: Torben Noerup Nielsen who wrote (15658)	2/23/1998 12:30:00 PM
From: Flagrante Delictu	Read Replies (1) \| Respond to of 32384

Torben, Re: LGND being "different from the run-of-the mill biotechs" The corporate name, Ligand Pharmaceuticals, seems to point at their aspirations. With a management composed of high ranking operatives from various top pharmas, as well as a stated mission to become a niche pharma in cancer, women's & men's health, metabolic, and now, possibly endocrine & atherosclerotic indications, the hiring of sales & marketing execs loudly proclaims their intention of "going for it" { If you will pardon the expression} . They've done it before with prior employers. They can't wait to do it for themselves { & us}. Godspeed. Bernie